Academic Journal
Localized unresectable neuroblastoma: results of treatment based on clinical prognostic factors
| العنوان: | Localized unresectable neuroblastoma: results of treatment based on clinical prognostic factors |
|---|---|
| المؤلفون: | Garaventa, A., Boni, L., Lo Piccolo, M. S., Tonini, G. P., Gambini, C., Mancini, A., Tonegatti, L., Carli, M., di Montezemolo, L. C., Di Cataldo, A., Casale, F., Mazzocco, K., Cecchetto, G., Rizzo, A., De Bernardi, B. |
| بيانات النشر: | Oxford University Press |
| سنة النشر: | 2002 |
| المجموعة: | HighWire Press (Stanford University) |
| مصطلحات موضوعية: | Miscellaneous tumors |
| الوصف: | Background We previously reported that stage 3 neuroblastoma comprises (i) a low-risk group including all infants (age 0–11 months) as well as older children with non-abdominal primaries, and (ii) a high-risk group made up of children >1 year of age with abdominal primaries. Aggressive chemotherapy was effective only in the latter group. Patients and treatment On this basis, in 1990 we designed a new protocol by which all low-risk patients received standard-dose chemotherapy, while the high-risk ones received very aggressive chemotherapy. Results Between November 1990 and December 1997 a total of 95 eligible and evaluable children were enrolled: 47 were low-risk (35 infants and 12 >1 year of age at diagnosis and having non-abdominal primaries), and 48 were high-risk (being >1 year of age and having abdominal primaries). Of the 47 low-risk patients, five relapsed and four subsequently died. The 5-year overall survival (OS) was 91%. Of the 48 patients in the high-risk group, 22 relapsed or progressed, 18 of whom died from their disease and two from toxicity, and one was lost to follow-up. The 5-year OS was 60%. Univariate analysis showed that age, site of primary, risk-group, urine vanillylmandelic excretion, plasma levels of lactate dehydrogenase, ferritin and neurone-specific enolase, and MYCN status correlated with outcome. However, multivariate analysis showed that only MYCN status retained prognostic value. Conclusions In low-risk stage 3 neuroblastoma, standard-dose chemotherapy is associated with an excellent chance of being cured. Aggressive chemotherapy is effective for high-risk patients, but results are still unsatisfactory. MYCN gene amplification is a prognostic indicator for most, but not all, treatment failures. |
| نوع الوثيقة: | text |
| وصف الملف: | text/html |
| اللغة: | English |
| Relation: | http://annonc.oxfordjournals.org/cgi/content/short/13/6/956; http://dx.doi.org/10.1093/annonc/mdf165 |
| DOI: | 10.1093/annonc/mdf165 |
| الاتاحة: | http://annonc.oxfordjournals.org/cgi/content/short/13/6/956 https://doi.org/10.1093/annonc/mdf165 |
| Rights: | Copyright (C) 2002, European Society for Medical Oncology |
| رقم الانضمام: | edsbas.3483AFBF |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/annonc/mdf165 |
|---|